What's Happening?
Boehringer Ingelheim has transferred commercial rights for its digital therapeutic (DTx) for schizophrenia, CT-155, to Click Therapeutics. This move follows successful phase 3 trial results showing the app's effectiveness in reducing negative symptoms
of schizophrenia when used alongside standard treatment. Boehringer has invested $50 million in Click and promised commercial funding for the DTx's launch if approved by the FDA. The partnership, initially formed in 2020, includes multiple DTx apps and potential milestones worth $460 million. Boehringer continues to lead the phase 3 ENSPIRUS trial, assessing the app's real-world impact on healthcare service use.
Why It's Important?
The transfer of rights to Click Therapeutics signifies a strategic shift for Boehringer towards a more investor-focused role in digital health. CT-155 has the potential to become a first-in-class treatment for schizophrenia's negative symptoms, which are currently underserved by pharmacological therapies. This development could offer a digital alternative to cognitive behavioral therapy, improving access to mental health care. The partnership highlights the growing importance of digital therapeutics in addressing complex health issues and the potential for innovative solutions to enhance patient outcomes.
